Trial Profile
ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Linagliptin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ELMI
- 06 Oct 2023 Results assessing whether there is a relationship between vascular improvement and GFR dipping presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jul 2019 Status changed from recruiting to completed.
- 25 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.